SCHEMBL19975103

SCHEMBL19975103

CC(C)CC(C(=O)C(N)=O)N(C=O)Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 4/20 0.44
MMP3 P08254 3/20 0.44
MMP2 P08253 2/20 0.43
MMP9 P14780 2/20 0.43
MMP8 P22894 2/20 0.43
MMP7 P09237 1/20 0.43
LTA4H P09960 1/20 0.40
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
CTSB P07858 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
MMP13 P45452 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975073 0.89 MMP1 (0.46) MMP1MMP3MMP2MMP9MMP8
SCHEMBL19975346 0.86 MMP1 (0.48) MMP1MMP3MMP2MMP9MMP8
SCHEMBL19974954 0.85 MMP1 (0.46) MMP1MMP3MMP2MMP9MMP8
SCHEMBL19975236 0.81 MEN1 (0.41) MMP2MMP9MMP8MEN1KMT2A
SCHEMBL21183516 0.74 HPGD (0.46) MMP1MMP3MMP9MMP7MEN1
SCHEMBL15650705 0.74 MMP1 (0.50) MMP1MMP3MMP2MMP9MMP8
SCHEMBL15650703 0.74 MMP1 (0.50) MMP1MMP3MMP2MMP9MMP8
SCHEMBL19974876 0.73 MEN1 (0.47) MMP1MMP3MMP9MMP7MEN1
SCHEMBL3463975 0.73 MMP1 (0.44) MMP1MMP3MMP2MMP9MMP8
SCHEMBL3463972 0.73 MMP1 (0.44) MMP1MMP3MMP2MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C MMP1 3062/4885MMP3 1828/4885MMP2 946/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C MMP1 3363/4885MMP3 1985/4885MMP2 973/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C MMP1 3062/4885MMP3 1828/4885MMP2 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.